The FDA approved a subcutaneous starting dose for Leqembi in July 2026, branded as Leqembi Iqlik, making it the first anti-amyloid Alzheimer's treatment that can be both started and continued entirely through at-home injections. For families managing the logistics of Alzheimer's treatment, this is a meaningful, practical change, even though it does not alter the underlying debate about how much benefit these drugs actually provide.
Here is what changed, what has not, and what it means if a loved one is currently being treated for early Alzheimer's disease. This article is general information, not medical advice, and should not be used to start or change any treatment.
The biweekly infusion center visit has been the single biggest logistical barrier to starting Leqembi treatment.
What Just Got Approved
Leqembi, known generically as lecanemab, was originally approved in 2023 as a biweekly IV infusion delivered at a clinic or infusion center. In 2025, the FDA approved an at-home injectable option, but only for the maintenance phase of treatment that begins after the first 18 months. The new approval extends at-home dosing to the starting phase as well, meaning a patient can now begin and continue treatment entirely through weekly self-administered injections, expected to be available in the United States by late August 2026.
Why This Is a Big Deal for Families
The biweekly infusion center visit has been the single biggest logistical barrier to starting Leqembi treatment, particularly for families in more rural or spread-out areas without easy access to an infusion center. Removing that requirement matters most for exactly the kind of desert and inland communities Angel's Haven Care serves, where the nearest infusion center may be a significant drive away.
What the Dosing Schedule Actually Looks Like
For patients starting treatment, the approved regimen involves two injections delivered once a week, each taking about fifteen seconds to administer, for the initial 18-month phase. After that period, patients who continue treatment shift to a lower weekly maintenance dose.
The Approved Dosing Regimen
In practice, this means a caregiver or the patient themselves needs to be comfortable with a brief, routine self-injection on a consistent weekly schedule, which is a very different logistical commitment than driving to an infusion center every other week.
What Has Not Changed
Eligibility still requires a confirmed amyloid-positive diagnosis and a physician evaluation. Periodic MRI monitoring is still required to watch for ARIA, a known side effect involving brain swelling or bleeding, regardless of whether the drug is delivered by injection or IV. This is not an over-the-counter medication, and it will be available exclusively through specialty pharmacy channels.
Worth noting: this article is general information, not medical advice. If your family is weighing whether Leqembi is the right option, that conversation belongs with the prescribing physician.
What This Approval Does Not Change About Cost
The switch to an at-home injection changes how the medication is delivered, but it does not change the underlying cost of treatment or the insurance coverage questions that come with it. Families considering Leqembi should expect the same conversations about coverage, copays, and specialty pharmacy logistics that existed before this approval, since the delivery method is a convenience change rather than a pricing change. Insurance coverage and out-of-pocket costs are worth confirming directly with the prescribing physician's office and the specialty pharmacy handling the medication, since details vary by plan.
What This Means If Your Loved One Is Already in Memory Care or Board and Care
If a resident is on or considering Leqembi treatment, coordination between the prescribing neurologist and the care setting matters, particularly around medication administration and monitoring for any side effects between scheduled MRI appointments. This is worth raising directly during a tour if it is relevant to your family's situation. You can read more about our approach to memory care on our Why Us page.
Talking to Your Loved One's Neurologist About This Option
This article is general information, not medical advice, and should not be used to start or change any treatment. If your family is weighing whether Leqembi is the right option, that conversation belongs with the prescribing physician, who can also speak to the broader question of how much clinical benefit to actually expect.
What to Expect in the First Few Weeks of At-Home Treatment
For families new to this kind of treatment, the first few weeks typically involve a training period with the prescribing office to make sure the injection technique is correct and comfortable, followed by a period of closer monitoring as the starting dose is established. It is normal for a physician's office to schedule more frequent check-ins during this early phase than they would once a patient has settled into the routine.
Building the injection into an existing daily or weekly routine, the same way many people manage other regular medications, tends to make the process feel less disruptive over time. For a resident in a board and care setting, this is also a reasonable thing to loop the care team in on, since consistency around timing and any noticed side effects benefits from more than one person tracking it.
Common Questions Families Ask
What is Leqembi Iqlik and how is it different from regular Leqembi?
Leqembi Iqlik is the subcutaneous, at-home injectable version of lecanemab. As of the 2026 approval, it can now be used for both the initial and maintenance phases of treatment, not just maintenance.
Quick Takeaway
The new at-home starting dose removes the biggest logistical hurdle to Leqembi treatment, the biweekly infusion center visit, but eligibility requirements and MRI monitoring for safety have not changed.
Does the at-home injection still require MRI monitoring?
Yes. Periodic MRI monitoring for ARIA is still required regardless of whether the medication is delivered by injection or IV infusion.
When will the at-home starting dose be available?
The commercial launch is expected in late August 2026, available through specialty pharmacy.
Who is eligible for Leqembi treatment?
Eligibility requires a confirmed amyloid-positive diagnosis and evaluation by a physician, typically for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Who actually gives the injection at home, the patient or a caregiver?
It depends on the individual's ability and comfort level. Some patients self-administer, while others rely on a caregiver or family member, and the prescribing physician's office typically provides training on the proper technique before treatment begins.
This article is general information, not medical advice. Do not start or change any Alzheimer's treatment based on this article alone; talk with the prescribing physician. If you have questions about memory care support at one of our homes, reach out through our Contact Us page or call (951) 900-4326. We are available Monday through Sunday, 8:00 AM to 8:00 PM.
Ask Us About Memory Care Support
Quick takeaway: the new at-home starting dose removes the biggest logistical hurdle to Leqembi treatment, but eligibility requirements and MRI monitoring for safety have not changed.
Talk to Our Team →